About Cerebrum Matter
Our idea of digital healthcare came to the fore in 2016 when the company’s bootstrapping stage, leading to the idea of a therapy software highly focused on Mental well-being. The development of the software tunnelled into the R&D process by end of 2017, leading us to start working on conducting a clinical trial with people to develop an evidence-based product aiming sincerely at treating cognitive declination, depression, anger & anxiety, the logical reasoning which are considered to leading onset symptoms of dementia using brainwave analysis.
Changing the Game for Healthy Ageing
While the use of medication is undoubtedly vital in helping both severe and light sufferers of dementia, Cerebrum Matter believes that dementia prevention is still an underdeveloped form of treatment that could potentially change the way the earlier stages of dementia are treated; if rights products and innovation are applied. While the ‘brain training’ software market is relatively crowded, Cerebrum Matter will have a clinically validated product classified as a medical device, and also with our developing advanced brainwave technology we are aiming to provide a personalised experience of cognitive improvement according to each individuals’ brain functionalities.
To prevent and reduce the prevalence of the symptoms of early onset dementia, by promoting mental wellness and thus leading to longer and higher quality independent lives to the elderly.
To become a Global leader in the field of cognitive therapy focused brainwave technology, leading to a significant reduction in the estimated numbers of future potential victims of dementia.
THE CERERBUM MATTER TEAM
Miss Kartheka Bojan, Founder & CEO of Cerebrum Matter Ltd, a digital healthcare start-up working on early dementia. She holds an MSc in Biomedical Engineering from the University of Nottingham. After working at IBM India, she spent 5 years in the UK developing medical devices.
She is the author of pending patents in EEG technology for Alzheimer’s & a Glucose Monitoring device and has also published work on Design of Biosensors with Gold Nanoparticles.Her innovative technical and business skills have been recognized with awards from NASA, IEEE and Nottingham & Leicester Universities.
PROF. ELIZABETA MUKAETOVA
Director of Clinical Research
Prof.Elizabeta is chairman of Old Age Psychiatry, Leicester University and Clinical Lead for Validating the COSMA Software with early demented patients and responsible for clinical R&D of the project. Her areas of academic interest include developing biomarkers with high sensitivity and specificity to detect various forms of dementia, and their implementation in routine clinical setting with an aim to monitor the progression of the disease and treatment.
University of Leicester
Chinese National Healthy Living Centre